About US
Contact us
-
2010 H1 report: Jiangsu Kanion Pharmaceutical (600557.SH)BEIJING, Jul 25, 2010 (Xinhua via COMTEX) -- The following is a table showing the main business indicators for the first half of 2010 of Shanghai-listed Jiangsu Kanion Pharmaceutical Co. Ltd. (600552010/7/26
-
Caraco Pharmaceutical Laboratories begins marketing bupropion hydrochloride extended release tabletsCaraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has started shipping bupropion hydrochloride extended release tablets. This product was recently approved by the US Food and Drug Administrati2010/7/23
-
Voreloxin and Cytarabine Combination Gets EU PatentThe European Patent Office (EPO) has issued a European patent covering combinations of Sunesis Pharmaceuticals' drug candidate voreloxin with cytarabine. Cytarabine is the standard-of-care treatment2010/7/23
-
FDA Approves Bacterial Vaginosis Drug TrialStarpharma Holdings has received US Food and Drug Administration (FDA) approval to begin a Phase II study to investigate VivaGel for the treatment of bacterial vaginosis. More than 130 women are enr2010/7/23
-
Eli Lilly completes Alnara acquisitionEli Lilly and Company (NYSE: LLY) today announced that it has completed the acquisition of Alnara Pharmaceuticals, Inc., a privately-held company developing protein therapeutics for the treatment of2010/7/22
-
Genentech disappointed with FDA ODAC's recommendation against AvastinGenentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one2010/7/22
-
European marine and algae oil omega-3 ingredient market to grow at 10% CAGR to reach $525.6M in 2013The flood of scientific evidence on omega-3 eicosapentaenoic acid/docosahexaenoic acid (EPA/DHA) has significantly buoyed the credibility of polyunsaturated fatty acids (PUFAs) as vital functional i2010/7/21
-
NanoViricides presents study results of nanoviricides anti-Ebola agentsNanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reports that the results of the evaluation of several of its nanoviricides® anti-Ebola agents were presented July 17th at the Annual Meeting o2010/7/21
-
Fero Industries provides comments concerning FDA advisory panel recommendation on diabetes drug AvandiaFero Industries, Inc. (FROI - OTCBB) (the "Company") is pleased to provide these comments regarding the recent Food and Drug Administration ("FDA") advisory panel recommendation concerning the Glaxo2010/7/21
-
Eisai's NDA for BANZEL Oral Suspension accepted for FDA reviewEisai Inc. (Headquarters: Woodcliff Lake, NJ; President and CEO: Lonnel Coats), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) today announced that the U.S.2010/7/20